References
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132: 474–9.
- Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5-a-reductase inhibitors and a-adrenergic antagonists. Mayo Clin Proc. 1993; 68: 670–9.
- Roos NP. Wennberg JE. Malenka DJ et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989; 20: 1120–24.
- Stoner E. The clinical development of a S-α-reduc tase inhibitor finasteride. J Steroids Biochem Mol Biol 1990; 37: 375–8.
- Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochcmical efficacy after single and multiple oral administration of N-[2-methyl-2-propyl]-3-oxo-4-aza-5a-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinetics. 1991; 16: 15–21.
- Carlin JR, Htiglund P, Eriksson LO et al. Disposition and pharmacokinetics of 14C finasteride after oral administration in humans. Drug Metabolism and Disposition. 1992; 20: 148–50.
- Stoner EH and the Finasteride Study Group. The clinical effects of a 5 a-reductase inhibitor, finasteride. on benign prostatic hyperplasia. J Urol 1992; 147: 1298–302.
- Gormley GJ, Stoner E. Uruskewitz RCS et al. The effcct of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992; 327: 1185–91.
- Guess HA. Heyse JF, Gormley GJ. The effect ol finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 199322: 31–7.
- Nau JY. L’industrie de l’addnome de la prostate. Le Monde, 2juin 1993; p. 17.